Tech Company Financing Transactions
Corsair Pharma Funding Round
On 9/21/2023, Corsair Pharma raised $23 million in Series B investment from New Rhein Healthcare Investors, Junson Capital and Midas Capital.
Transaction Overview
Company Name
Announced On
9/21/2023
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds for the clinical advancement of its patch.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1230 Bordeaux Drive
Sunnyvale, CA 94089
USA
Sunnyvale, CA 94089
USA
Phone
Undisclosed
Website
Email Address
Overview
Corsair Pharma is developing transformative solutions to improve the therapeutic profile of medications and provide superior treatment options for patients. The company's first product candidate is a prodrug of treprostinil delivered on a proprietary transdermal patch to treat pulmonary arterial hypertension (PAH). Corsair also believes that their transdermal patch has the potential in other forms of pulmonary hypertension. The company has a strategic partnership with United Therapeutics, the market leader in PAH therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
President
Bobby Singh
Browse more venture capital transactions:
Prev: 9/21/2023: Medeloop venture capital transaction
Next: 9/21/2023: Mundial Media venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs